

06/14/00

jc535 U.S. PTO

jc531 U.S. PTO

09/593401

06/14/00

Please type a plus sign (+) inside this box → ☐

Approved for use through 09/30/2000. OMB 0651-0032  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 44892

First Inventor or Application Identifier PRASAD, Kailash

Title USE OF PURIFIED SDG AS A HYPOTENSIVE  
(VASODILATOR) AGENT

Express Mail Label No.

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
 (Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 15]  
 (preferred arrangement set forth below)
- Descriptive title of the invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 9]
4. Oath or Declaration [Total Pages 2]
- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
 (for continuation/divisional with Box 16 completed)
- i. ☐ DELETION OF INVENTOR(S)  
 Signed statement attached deleting  
 inventor(s) named in the prior application,  
 see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

\* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY  
 FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT  
 IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents  
 Box Patent Application  
 Washington, DC 20231

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission  
 (if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

7. ☒ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement of Power of Attorney  
 (when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 [Copies of IDS Citations]
11. ☐ Preliminary Amendment
12. ☐ Return Receipt Postcard (MPEP 503)  
 (Should be specifically itemized)
13. ☐ \* Small Entity Statement filed in prior application,  
 Statement(s) Status still proper and desired  
 (PTO/SB/09-12)
14. ☐ Certified Copy of Priority Document(s)  
 (if foreign priority is claimed)
15. ☐ Other:

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. \_\_\_\_\_

Prior application information: Examiner \_\_\_\_\_

Group / Art Unit: \_\_\_\_\_

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name	Norris M. Eades				
Address	KIRBY EADES GALE BAKER P.O. Box 3432, Station D				
City	Ottawa	State	Ontario	Zip Code	K1P 6N9
Country	CANADA	Telephone	(613) 237-6900	Fax	(613) 237-0045

Name (Print/Type)	Norris M. Eades	Registration No. (Attorney/Agent)	25,263
Signature		Date	Aug 13 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**STATEMENT CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) & 1.27(d))--NONPROFIT ORGANIZATION**

Docket Number (Optional)  
44892

Applicant, Patentee, or Identifier: PRASAD, Kailash

Application or Patent No.: \_\_\_\_\_

Filed or Issued: \_\_\_\_\_

Title: USE OF PURIFIED SDG AS A HYPOTENSIVE (VASODILATOR) AGENT

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION University of Saskatchewan Technologies Incorporated

ADDRESS OF NONPROFIT ORGANIZATION Room 304, Kirk Hall, 117 Science Place,  
Saskatoon, Saskatchewan, Canada S7N 5C8

**TYPE OF NONPROFIT ORGANIZATION:**

☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION

☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3))

☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA  
(NAME OF STATE \_\_\_\_\_ )  
(CITATION OF STATUTE \_\_\_\_\_ )

☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3))  
IF LOCATED IN THE UNITED STATES OF AMERICA

☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED  
STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA  
(NAME OF STATE \_\_\_\_\_ )  
(CITATION OF STATUTE \_\_\_\_\_ )

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.  
☐ the patent identified above.

I hereby state that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization having any rights in the invention is listed below:

- ☒ no such person, concern, or organization exists.  
☐ each such person, concern, or organization is listed below.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Branks F. Peterman

TITLE IN ORGANIZATION OF PERSON SIGNING President & CEO

ADDRESS OF PERSON SIGNING 304 Kirk Hall, 117 Science Place, Saskatoon, SK

SIGNATURE B. F. Peterman DATE June 12, 2000

USE OF PURIFIED SDG AS A HYPOTENSIVE (VASODILATOR) AGENTBackground of the Invention

This invention relates to the use of purified SDG (secoisolariciresinol diglucoside) as a hypotensive (vasodilator) agent in treating hypertension or reducing or preventing the development of elevated blood pressure.

Hypertension is one of the leading causes of deaths in this society. According to a survey done between 1986-1992, the overall prevalence of hypertension in the Canadian population was 22% and was higher in men (26%) than in women (18%). There is overwhelming evidence that elevated systolic or diastolic blood pressure or both, increases the probability of ischemic heart disease, stroke, atherosclerosis and overall mortality. The causes of death in hypertensive are heart failure (45%), heart attack (35%), stroke (15%) and kidney failure (5%). Treatment and control of high blood pressure reduce the risk of ischemic heart disease and stroke. Ischemic heart disease is the leading cause of death and hospitalization.

The present treatments of hypertension and ischemic heart disease have side effects and are expensive. The drugs used for treating hypertension include diuretics, antiadrenergic agents, vasodilator, central agonists, angiotensin converting enzyme inhibitors, calcium channel blockers, and angiotensin II receptor antagonists.

Diuretics reduce blood potassium, increase serum cholesterol, LDL-cholesterol and triglycerides, are diabetogenic, and produce gout. Beta-adrenergic blockers produce insomnia, fatigue, sexual dysfunction and exacerbation of asthma, increases serum cholesterol and triglycerides, and produce cold hands. Angiotensin converting enzyme inhibitors could cause cough, angioedema, urticaria and loss of white

blood and other blood cells. Calcium channel blockers produce flushing, headaches, palpitation and swelling of ankles.

For treatment of ischemic heart disease (angina pectoris, myocardial infarction) the physiologic basis of treatment with drugs are to reduce oxygen demand and increase oxygen supply. For this purpose, the vasodilator (nitrites and nitrates), beta-adrenergic blocker, calcium channel blockers are generally being used.

Nitrites and nitrates produce headache, flushing face, and reflex tachycardia. Reflex tachycardia would increase the oxygen consumption of the heart and hence would counteract to some extent the beneficial effect of nitrites and nitrates in ischemic heart disease. Also nitrites and nitrates produce tolerance.

The drugs used for the treatment of hypertension and ischemic heart disease are also very expensive. Side effects common to drugs, especially antihypertensive drugs, together with high cost of the drugs, have always been a major cause of noncompliance and concern. It is particularly difficult to accept treatment-related symptoms for a life-long disease, especially hypertension. For example, a research conducted by J. Menard [Improving hypertension treatment. Where should we put our efforts: new drugs, new concepts, or new management? (1992) Am. J. Hypertens. 5(12 Pt 2): 252S-258S] revealed that current treatment failure is frequent and side effects are common. The results showed that in the systolic hypertension in the elderly program, 28 to 35% of patients did not reach the goal blood pressure, 13% stopped treatment because of side effects, and 21% required medication other than a diuretic and a beta-blocker.

Therefore, despite the availability of numerous antihypertensive agents, a concerted research effort to develop new approaches to hypertension treatment is necessary.

Prasad, U.S. Patent 5,846,944 describes the use of purified SDG for the treatment of hypercholesterolemic atherosclerosis and for reducing total cholesterol, as well as for the treatment of diabetes mellitus. Atherosclerosis is lipid deposit in the arteries and hence narrowing of blood vessels, resulting in ischemic heart disease.

The literature also describes the beneficial effect of flaxseed to reduce ascites and pulmonary hypertension in broiler chickens [J. Bond et al. (1996) Effect of dietary flax oil and hypobaric hypoxia on right ventricular hypertrophy and ascites in broiler chickens. British Poultry Science 37(4): 731-741]. Researchers have also inferred a role for flax in diet of patients with ischemic heart disease, hyperlipidemia and high blood pressure. [I.A. Rozanova et al. (1997) Effect of antiatherosclerotic diet, containing polyunsaturated fatty acids of the omega-3 family from flax oil, on fatty acid composition of cell membranes of patients with ischemic heart disease. Vopr. Pitan. (5): 15-17]. It has been shown that alpha-linolenic acid has a beneficial effect in coronary heart disease, hypertension, and inflammatory disorders [E. Mantzioris et al. (1995) Differences exist in the relationships between dietary linoleic and alpha-linolenic acids and their respective long-chain metabolites. Am. J. Clin. Nutr. 61(2): 320-324]. Yet, little is known about the hypotensive effect of the lignan components of flaxseed. Moreover, use of whole flaxmeal or oil components of flaxseed has been found to result in progressive weight gain due to the high caloric value of the oil components.

Flaxseed is known to contain a myriad of molecules including lignan and oil fractions. Secoisolariciresinol diglucoside (SDG) is the principal lignan from flaxseed.

Although flaxseed has been used as an edible grain in different parts of the world since ancient times, use of flaxseed was limited due to the presence of cyanogenic

glucosides and diglucosides in the seeds as they may release cyanide upon hydrolysis. Also, flaxseed has to be used in large quantity to be effective.

In Westcott and Muir U.S. Patent 5,705,618, issued January, 1998, there is described a practical method of extracting and purifying SDG. By this technique, SDG can be obtained in a purity of greater than 95%.

The purpose of the present invention is to provide a method of using flaxseed for medical purposes without the aforementioned drawbacks of cyanogenic glycosides, and caloric loads. SDG compound is obtained from natural food product (flaxseed), and hence it is expected to have non or minimal side effect if any. It is also an inexpensive drug as compared to other conventional drugs used in the treatment of hypertension and ischemic heart disease.

#### Summary of the Invention

In accordance with this invention, it has been found that by administering SDG from flaxseed in substantially pure form to a human or non-human animal, elevated blood pressure can be reduced and hypertension can be prevented. The SDG serves to lower blood pressure by dilation of blood vessels. Its vasodilator (hypotensive) effect appears to be mediated primarily through the inhibition of guanylate cyclase, partly through inhibition of angiotensin I converting enzyme and blockade of angiotensin II receptor, and through histamine.

SDG is also useful for the treatment of ischemic heart disease (coronary artery disease) where the SDG serves to dilate the coronary blood vessels to supply more blood to the heart muscle. This abolishes ischemia of the heart and hence abolishes or prevents chest pain and other signs and symptoms associated with an ischemic heart. Also, by reducing the afterload (aortic pressure) because of lowering blood

pressure, SDG serves to decrease the myocardial oxygen consumption thereby reducing ischemia of the heart.

A further associated use of SDG is for treating intermittent claudication, which is a leg pain while walking due to narrowing of the blood vessels of a leg muscle. Decreased blood flow to the leg muscle initiates the pain. SDG by dilating blood vessels increases the blood supply to the leg muscle and relieves the leg pain.

A still further associated use of SDG is for the treatment of heart failure, where it serves to reduce the afterload to the heart by lowering blood pressure. Thus, the heart is able to work against low arterial pressure thereby increasing the cardiac output.

Diabetic patients are known to suffer hypertension and SDG is effective in lowering the blood pressure of hypertensive patients with diabetes.

Unlike the uses of SDG described in U.S. Patent 5,846,944, in the uses according to the present invention the SDG acts primarily to dilate blood vessels. This is achieved without the undesirable side effects of cyanogenic glycosides and caloric loads.

The SDG is preferably used at a high degree of purity of over 90%, with a purity of over 95% being the preferred. It can be administered orally, intraperitoneally or intravenously. It has been found to be highly effective in normotensives when given intravenously in the doses of 10-30 mg/kg body weight and in hypertensives when given intravenously in the doses of 1-15 mg/kg body weight, intraperitoneally in the doses of 5-200 mg/kg body weight, and orally in the dose of 100 mg/kg body weight. The oral doses may conveniently be in the form of tablets or capsules and the SDG may be used together with a variety of pharmaceutically acceptable diluents or carriers.

### Brief Description of the Drawings

In the drawings which illustrate the present invention:

Fig. 1 is a graph showing effects of four doses of SDG on the mean arterial blood pressure (B.P.) in anesthetized

5 normotensive rats; the results are expressed as mean  $\pm$  S.E.

Fig. 2 is a graph showing effects of four doses of SDG on the mean systolic blood pressure (B.P.) in anesthetized normotensive rats; the results are expressed as mean  $\pm$  S.E.

Fig. 3 is a graph showing effects of four doses of SDG on 10 the diastolic blood pressure (B.P.) in anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E.

Fig. 4 is a graph showing effects of four doses of SDG on the heart rate in anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E.

15 Fig. 5 is a graph showing changes in the mean arterial blood pressure (B.P.) with SDG (20 mg/kg, intravenously) in the absence or presence of methylene blue (MB) (0.5 mg/kg); methylene blue was given 15 minutes prior to administration of SDG and results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , 20 comparison of values at various times with respect to "0" time.

Fig. 6 is a graph showing effects of SDG (20 mg/kg, intravenously) on the systolic blood pressure (B.P.) in the absence or presence of methylene blue (MB) (0.5 mg/kg) in the 25 anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , comparison of values at various times with respect to "0" time.

Fig. 7 is a graph showing effects of SDG (20 mg/kg, intravenously) on the diastolic blood pressure (B.P.) in the 30 absence or presence of methylene blue (MB) (0.5 mg/kg) in the anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , comparison of values at various times with respect to "0" time.



Fig. 8 is a graph showing effects of SDG (20 mg/kg, intravenously) on the heart rate in the absence or presence of methylene blue (MB) (0.5 mg/kg) in anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E.

5 Fig. 9 is a graph showing effects of SDG in the absence or presence of pyrilamine on the mean arterial blood pressure (B.P.) in anesthetized normotensive rats. Pyrilamine was given 15 minutes before administration of SDG. The results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , comparison of values at  
10 various times with respect to "0" time.

Fig. 10 is a graph showing effects of SDG in the absence or presence of pyrilamine on the systolic blood pressure in anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , comparison of values at various times with  
15 respect to "0" time.

Fig. 11 is a graph showing effects of SDG in the absence or presence of pyrilamine on the diastolic pressure in anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , comparison of values at various times with  
20 respect to "0" time.

Fig. 12 is a graph showing effects of SDG in the absence or presence of pyrilamine on heart rate in anesthetized normotensive rats; results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , comparison of values at various times with respect to  
25 "0" time.

Fig. 13 is a graph showing the effect of angiotensin I (Ag I) on the mean arterial pressure of anesthetized Sprague-Dawley rats in the absence (blank bar) and in the presence of SDG (shaded bar); a line plot shows the effects of SDG (I.V.)  
30 on the mean arterial pressure as a function of time and the results are expressed as mean  $\pm$  S.E. \* $p < 0.05$ , comparison of the values at 15 minutes, 30 minutes and 60 minutes with respect to values at control (before any drug treatment).  
<sup>a</sup> $p < 0.05$ , 15 minutes vs 30 minutes or 60 minutes.

<sup>b</sup>p<0.05, 15 minutes vs 30 minutes or 60 minutes.

<sup>†</sup>p<0.05, control vs all other time-intervals.

Fig. 14 is a graph showing the effect of angiotensin II on the mean arterial pressure of anesthetized Sprague-Dawley rats in the absence (blank bar) and in the presence of SDG (shaded bar); a line plot shows the effects of SDG on the mean arterial pressure as a function of time and the results are expressed as mean  $\pm$  S.E.

\*p<0.05, comparison of the values at 15 minutes, 30 minutes and 60 minutes with respect to values at control (before any drug treatment).

<sup>†</sup>p<0.05, comparison of values at 15 minutes, 30 minutes and 60 minutes with respect to values at control.

<sup>b</sup>p<0.05, 15 minutes vs 30 minutes or 60 minutes.

<sup>c</sup>p<0.05, 30 minutes vs 60 minutes.

Fig. 15 is a graph showing the effects of intravenous administration of various doses (1 mg, 3 mg and 15 mg/kg body wt.) of SDG on the arterial pressures (systolic, diastolic and mean) in anesthetized spontaneous hypertensive rats observed for four hours; results are expressed as percent decrease.

Fig. 16 is a graph showing the effects of intraperitoneal administration of various doses of SDG (5 mg, 10 mg, 50 mg and 200 mg/kg body wt.) on the arterial pressures (systolic, diastolic and mean) in anesthetized spontaneous hypertensive rats observed for four hours; results are expressed as percent decrease.

Fig. 17 is a graph showing the effects of oral administration of SDG (100 mg/kg body wt.) on the arterial pressures (systolic, diastolic and mean) in anesthetized spontaneous hypertensive rats observed for four hours; the results are expressed as percent change from control taken as 100%.

## Description of the Preferred Embodiments

### Example 1

The effects of SDG in the doses of 10 mg, 15 mg, 20 mg and 30 mg/kg given intravenously were investigated on the blood pressure (B.P.) and heart rate of anesthetized normotensive rats. The number of rats used were 8, 3, 9, and 3 respectively for the doses of SDG (10 mg, 15 mg, 20 mg and 30 mg/kg body wt.). The effects of various doses of SDG on mean, systolic and diastolic blood pressures and heart rate are summarized in Figures 1-4. The maximum fall in mean B.P. were approximately 38%, 29%, 46% and 57% with 10 mg, 15 mg, 20 mg and 30 mg/kg dose of SDG respectively at 15 minutes after administration of SDG. After 15 minutes the blood pressure tended to recover but the recovery was not complete. The mean blood pressure at the end of three hours after SDG administration were approximately 25% lower than control values. The changes in the systolic and diastolic pressure were similar to the mean blood pressure with various doses of SDG. These results suggest that SDG has hypotensive effect and that this effect is of long duration. One would expect a very long duration of hypotensive effect when SDG is given orally.

The heart rate was not significantly altered by any dose of SDG (Fig. 4).

Hypotensive effect of SDG was not prevented by premedication with atropine (acetylcholine receptor blocker),  $N^G$ -monomethyl-L-arginine (an inhibitor of nitric oxide synthase) and indomethacin (an inhibitor cyclooxygenase), suggesting that hypotensive effect of SDG is not mediated by acetylcholine, nitric oxide or arachidonic acid vasodilator metabolites. However the hypotensive effect of SDG was completely prevented by methylene blue (a guanylate cyclase inhibitor) (Figs. 5-7) suggesting that hypotensive effect of

SDG is mediated by guanylate cyclase. Heart rate was not affected by methylene blue (Fig. 8). Hypotensive effect of SDG is also partly prevented by pyrilamine (histamine receptor blocker) (Figs. 9-11), suggesting the hypotensive effect is mediated partly through histamine. Heart rate was practically unchanged (Fig. 12).

These results indicate that SDG is a hypotensive agent and this effect is not associated with reflex tachycardia. The mechanism of vasodilation (hypotension) is similar to nitrites used in patients with ischemic heart disease.

#### Example 2

Further experiments were conducted to determine if the SDG-induced fall in the blood pressure is mediated through inhibition of angiotensin converting enzyme (ACE).

Angiotensin I is converted to angiotensin II which is vasoconstrictor and raises blood pressure. If SDG lowers blood pressure by inhibiting ACE, then SDG would reduce/prevent the angiotensin I-induced rise in the blood pressure. Experiments were conducted in six normotensive Sprague-Dawley rats. The effects of angiotensin I ( $0.2 \mu\text{g/kg}$ ) given intravenously at various intervals before and after administration of SDG ( $10 \text{ mg/kg}$ ) intravenously were observed for 60 minutes. Control effects of angiotensin I were observed for similar duration in the absence of SDG. The results are summarized in Figure 13. There was a marked reduction in the response of angiotensin I on the mean arterial pressure in SDG-treated rats. However, the effects of angiotensin on arterial pressure of untreated rats remained unaltered. SDG ( $10 \text{ mg/kg}$ ) produced a marked fall in the mean arterial pressure. These results indicate that hypotensive effects of SDG is partially mediated through the inhibition of ACE.

Example 3

To determine if the SDG-induced fall in the blood pressure is mediated through the blockade of angiotensin II receptor, experiments were carried out in normotensive Sprague-Dawley rats. Effects of angiotensin II (0.2  $\mu$ g/kg, I.V.) given before and after 15 minutes, 30 minutes and 60 minutes of SDG (10 mg/kg) administered intravenously were investigated on the arterial pressure of six anesthetized Sprague-Dawley rats. The results are summarized in Figure 14. Angiotensin II response was moderately reduced in the presence of SDG. The response of angiotensin II on the mean arterial pressure in untreated rats remained unaltered. SDG as usual reduced the mean arterial pressure.

These results indicate that SDG-induced fall in the blood pressure is partially mediated through blockade of angiotensin II receptor.

Example 4

The effects of SDG on the arterial pressure of anesthetized spontaneous hypertensive rats (SHR) were investigated to determine (a) if it is effective in lowering blood pressure to the same extent as in normotensive Sprague-Dawley rats; (b) if it is effective when given by intraperitoneal route; (c) if the effect is dose-dependent.

(i) Effects of SDG in the doses of 1 mg, 3 mg and 15 mg/kg given intravenously were investigated on the blood pressures of anesthetized spontaneous hypertensive rats (SHR). The preliminary results are shown in Figure 15. The maximum fall in the blood pressure occurred between 15 to 30 minutes of SDG administration after which the blood pressure tended to recover. However, the recovery was short lived. The percent decreases in blood pressures at 30 minutes after SDG were 19, 25 and 31 respectively with 1 mg, 3 mg and 15 mg/kg of SDG. At the end of 4 hours of SDG treatment, the percent decreases

were 34, 43 and 36 respectively with 1 mg, 3 mg and 15 mg dose. The fall in the blood pressure initially (at 15 minutes) was maximum with high dose of SDG.

These results indicate that SDG has hypotensive effect, has long duration of action and the effect is dose-dependent. The effects appear to be greater in hypertensive than normotensive rats.

(ii) Effects of SDG in the doses of 5 mg, 10 mg, 50 mg and 200 mg/kg given intraperitoneally were investigated on blood pressure of anesthetized SHR for four hours. The preliminary results are shown in Figure 16. The maximum fall in the blood pressure were approximately 7, 37, 50 and 48% respectively with 5 mg, 10 mg, 50 mg and 200 mg of SDG at 30 minutes. At the end of four hours of SDG administration the percent decreases in blood pressures were 31, 42, 39 and 37 respectively with these four doses of SDG.

These results indicate that SDG given intraperitoneally is hypotensive, has long duration of action, and its effect is dose-dependent.

(iii) Effects of SDG (100 mg/kg body wt.) given orally were investigated on the blood pressure of anesthetized spontaneous hypertensive rats for four hours. The preliminary results are shown in Figure 17. The blood pressures began falling at 15 minutes of SDG administration and maximum fall occurred after three hours. The decreases were of similar magnitude for systolic, diastolic and mean arterial pressures. The systolic, diastolic and mean arterial pressures respectively were 243 mmHg, 176 mmHg and 198 mmHg before administration of SDG. SDG reduced the blood pressure by approximately 25%.

These results indicate that SDG is effective in lowering blood pressure given orally.

Claims

1. A method for treating hypertension or for reducing or preventing development of elevated blood pressure which comprises administering to a patient an effective amount of secoisolariciresinol diglucoside (SDG) in substantially pure form.
2. A method according to claim 1 wherein the SDG is obtained from flaxseed.
3. A method according to claim 1 wherein the SDG has a purity of at least 95%.
4. A method according to claim 3 wherein the SDG is administered in an amount of 10-30 mg/kg of body weight in a normotensive patient.
5. A method according to claim 3 wherein the SDG is administered in an amount of 1-15 mg/kg of body weight in a hypertensive patient.
6. A method for treating ischemic heart disease which comprises administering to a patient an effective amount of SDG in substantially pure form.
7. A method according to claim 6 wherein the SDG is obtained from flaxseed.
8. A method according to claim 7 wherein the SDG has a purity of at least 95%.
9. A method for treating heart failure which comprises administering to a patient an effective amount of SDG in substantially pure form.
10. A method according to claim 9 wherein the SDG is obtained from flaxseed.

5

5








FIG. 1




FIG. 2

09593401-061400




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14






FIG. 15




FIG. 16

09593401-061400




FIG. 17

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

☒ Declaration Submitted with Initial Filing OR ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number 44892

First Named Inventor PRASAD, Kailash

**COMPLETE IF KNOWN**

Application Number /

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

USE OF PURIFIED SDG AS A HYPOTENSIVE (VASODILATOR) AGENT

the specification of which

(Title of the invention)

☒ is attached hereto  
OR

☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International

Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
60/140,972	06/16/1999	

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number  OR ☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Norris M. Eades	25,263	Kimberley A. Lachaine	33,319
Edwin J. Gale	28,584	Robert K. Feutlinske	37,994
John A. Baker	26,656	Andrew J. Bauer-Moore	44,449


☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number  OR ☒ Correspondence address below

Name	NORRIS M. EADES,				
Address	KIRBY, EADES, GALE, BAKER,				
Address	P.O. Box 3432, Station D,				
City	Ottawa	State	Ontario	ZIP	K1P 6N9
Country	CANADA	Telephone	(613) 237-6900	Fax	(613) 237-0045

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname	
Kailash		Prasad	
Inventor's Signature			Date
Residence: City	Saskatoon	State	Saskatchewan
		Country	Canada
		Citizenship	CA
Post Office Address	358 Assiniboine Drive		
Post Office Address			
City	Saskatoon	State	Saskatchewan
		ZIP	S7K 3Z2
		Country	Canada

☐ Additional inventors are being named on the \_\_\_\_\_ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto